A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Date publication

décembre 2017

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice

Tous les auteurs :
Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, Hollebecque A, Azaro A, Hervieu A, Rihawi K, De Marinis F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29145039

Résumé

Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation.

Mots clés

Adult, Aged, Antineoplastic Agents, administration & dosage, Benzothiazoles, administration & dosage, Biomarkers, Tumor, antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung, drug therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Europe, Female, Gene Amplification, Humans, Lung Neoplasms, drug therapy, Male, Maximum Tolerated Dose, Middle Aged, Protein Kinase Inhibitors, administration & dosage, Proto-Oncogene Proteins c-met, antagonists & inhibitors, Signal Transduction, drug effects, Time Factors, Treatment Outcome, United States, Urea, administration & dosage

Référence

Eur. J. Cancer. 2017 12;87:131-139